Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Estrogen lowers triglyceride via regulating hepatic APOA5 expression.

Luo F, Guo Y, Ruan GY, Peng R, Li XP.

Lipids Health Dis. 2017 Apr 4;16(1):72. doi: 10.1186/s12944-017-0463-0.

3.

Progestogens in menopausal hormone therapy.

Bińkowska M, Woroń J.

Prz Menopauzalny. 2015 Jun;14(2):134-43. doi: 10.5114/pm.2015.52154. Epub 2015 Jun 22. Review.

4.

Lipoprotein subclasses and endogenous sex hormones in women at midlife.

El Khoudary SR, Brooks MM, Thurston RC, Matthews KA.

J Lipid Res. 2014 Jul;55(7):1498-504. doi: 10.1194/jlr.P049064. Epub 2014 May 22.

5.

Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women.

Smith GI, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1306-10. doi: 10.1210/jc.2013-4470. Epub 2014 Apr 2.

6.

Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.

Cai A, Li L, Zhang Y, Mo Y, Mai W, Zhou Y.

Dis Markers. 2013;35(5):551-9. doi: 10.1155/2013/563717. Epub 2013 Oct 22. Review.

7.

A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.

Deligiannidis KM, Rothschild AJ, Barton BA, Kroll-Desrosiers AR, Meyers BS, Flint AJ, Whyte EM, Mulsant BH; STOP-PD Study Group..

J Clin Psychiatry. 2013 Oct;74(10):1003-9. doi: 10.4088/JCP.13m08400.

8.

The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program.

Golden SH, Kim C, Barrett-Connor E, Nan B, Kong S, Goldberg R; Diabetes Prevention Program Research Group..

Metabolism. 2013 Sep;62(9):1313-22. doi: 10.1016/j.metabol.2013.04.005. Epub 2013 May 6.

9.

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr.

Endocr Rev. 2013 Apr;34(2):171-208. doi: 10.1210/er.2012-1008. Epub 2012 Dec 13. Review.

10.

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Hoover-Plow J, Huang M.

Metabolism. 2013 Apr;62(4):479-91. doi: 10.1016/j.metabol.2012.07.024. Epub 2012 Oct 4. Review.

11.

Effects of Erxian decoction, a Chinese medicinal formulation, on serum lipid profile in a rat model of menopause.

Sze SC, Cheung HP, Ng TB, Zhang ZJ, Wong KL, Wong HK, Hu YM, Yow CM, Tong Y.

Chin Med. 2011 Nov 2;6:40. doi: 10.1186/1749-8546-6-40.

12.

Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones.

Wang X, Magkos F, Mittendorfer B.

J Clin Endocrinol Metab. 2011 Apr;96(4):885-93. doi: 10.1210/jc.2010-2061. Review.

13.

Estrogen deficiency after menopause does not result in male very-low-density lipoprotein metabolism phenotype.

Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S, Mittendorfer B.

J Clin Endocrinol Metab. 2010 Jul;95(7):3377-84. doi: 10.1210/jc.2010-0341. Epub 2010 May 5.

14.

Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?

Nott SL, Huang Y, Fluharty BR, Sokolov AM, Huang M, Cox C, Muyan M.

Curr Pharmacogenomics Person Med. 2008 Dec 1;6(4):239-259.

15.

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.

Suk Danik J, Rifai N, Buring JE, Ridker PM.

J Am Coll Cardiol. 2008 Jul 8;52(2):124-31. doi: 10.1016/j.jacc.2008.04.009.

16.

Supplemental Content

Support Center